MarcChamberlainMD

Neurology • Seattle, WA

Neurooncology, Child Neurology

Professor of Neurology, University Wash

Join to view full profile

Are you Dr. Chamberlain?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 71 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
Seattle Cancer Care Alliance
825 Eastlake Ave E Ms G-6800 Pob 19023
Seattle, WA 98109
Phone+1 813-362-4370

Summary

Dr. Marc Chamberlain, MD is a neurologist in Seattle, Washington. He is currently licensed to practice medicine in Washington. He is affiliated with UW Medicine/University of Washington Medical Center and Seattle Children's Hospital.

Education & Training

University of California (San Francisco)Residency, Neurological Surgery, 1985 - 1986
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Child Neurology, 1982 - 1985
Los Angeles County-Harbor-UCLA Medical CenterResidency, Pediatrics, 1979 - 1980
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1977 - 1979
Columbia University Vagelos College of Physicians and SurgeonsClass of 1977

Certifications & Licensure

WA State Medical License 2007 - 2017

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma Start of enrollment: 2006 Jul 01
Terminated
Phase 2
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Start of enrollment: 2008 Aug 01
Unknown status
Phase 1, Phase 2
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Start of enrollment: 2008 Oct 01
Completed
Phase 2
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2013 Jul 18
Completed
Phase 1, Phase 2
ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma Start of enrollment: 2016 Apr 08
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

387 citations
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
M. J. van den Bent, Jeffrey S. Wefel, David Schiff, Martin J.B. Taphoorn, Kurt A. Jaeckle
The Lancet. Oncology. 2011-06-01
43 citations
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
Marc C. Chamberlain, Sean Grimm, Surasak Phuphanich, Lawrence Recht, Jay-Jiguang Zhu
Journal of Neuro-Oncology. 2014-04-17
102 citations
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin, Carla I. Falkson, Qamar Khan
JAMA Oncology. 2018-09-01

Press Mentions

Lantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 14th, 2024

Professional Memberships

American Academy of Neurology - AAN
Member